Twist Bioscience Shares Jump on Record Revenue, Raised Guidance and Path to Profitability
Twist Bioscience shares rose after record $118.4M Q3 revenue (+23% YoY), 14th sequential growth quarter, raised FY26 outlook, and path to EBITDA breakeven.
/ 57 items
#XY Earnings Movers↓
Krystal Biotech Q2 2026: Solid Growth, Strong Cash, But Revenue Shortfall Triggers Sell-Off
Krystal Biotech shares dropped after Q2 revenue missed forecasts, despite strong earnings, growth, and progress with VYJUVEK sales.
TG Therapeutics Shares Fall on EPS Miss Despite Strong BRIUMVI Sales and Raised Guidance
TG Therapeutics saw strong BRIUMVI sales and raised forecasts, but higher costs caused a major earnings miss, pushing shares lower.
Neurocrine Stock Weak Despite Strong Q2 Beat and Raise; Analysts Call Dip “Overdone”
Neurocrine reported $959M Q2 revenue (+39%) and raised Ingrezza guidance. Stock fell on short-term concerns, but analysts call the dip overdone and raise targets.
Moderna Beats Revenue Estimates on Strong COVID Sales, but Shares Drop on Norovirus Setback
Moderna reported $145M Q2 revenue, beating $103M estimates on strong COVID vaccine sales. Shares fell after norovirus vaccine missed key trial goal.
Alnylam Stock Crashes Nearly 30% as Company Lowers Full-Year Revenue Outlook
Alnylam cuts 2026 Amvuttra sales guidance to $4.2B–$4.5B due to slower growth in second-line ATTR-CM demand.